Gastroesophageal adenocarcinoma
Therapeutic area
Oncology
Rare disease
No
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Gastroesophageal adenocarcinoma
- Therapeutic area
- Oncology
- gastroesophageal adenocarcinoma
- Advanced Gastroesophageal Adenocarcinoma
- Metastatic Gastroesophageal Adenocarcinoma
- All therapeutic areas
- Oncology
Sources for recorded values
- Severity
- Severe
- MONDO ID
- MONDO:0850130
- Parent condition
- MONDO:0004970
Related records
Broader conditions (11)
- Adenocarcinoma
- Cancer
- Cancer or benign tumor
- Carcinoma
- Disease
- Disease by etiologic mechanism
- Epithelial neoplasm
- Glandular cell neoplasm
- Human disease
- Neoplasm
- Neoplastic disease or syndrome
Trials (31)
- A Clinical Trial Evaluating TQB2102 for Injection in Combination With Behmosubaisumab/Payamprolizumab With or Without Chemotherapy in Unresectable Locally Advanced, Recurrent, or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastroesophageal Adenocarcinoma
- A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors
- A First-in-Human Study Using BDC-4182 as a Single Agent in Advanced Gastric and Gastroesophageal Cancer
- A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers
- A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors.
- A Study of a Personalized Neoantigen Cancer Vaccine
- A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma
- A Study of Personalized Neoantigen Cancer Vaccines
- A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
- AACR Adaptive Biomarker-Driven Organ Preservation Trial in Gastroesophageal Adenocarcinomas
- Adebrelimab Combined With Induction Chemotherapy or SHR-8068 for Mismatch Repair-Deficient/Microsatellite Instability-High (dMMR/MSI-H) Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinomaļ¼A Randomized, Non-comparative Phase 2 Study
- Adebrelimab With Chemoradiotherapy and Surgery for G/GEJ
- Alisertib in Adults With Nonhematological Malignancies, Followed by Alisertib in Lung, Breast, Head and Neck or Gastroesophageal Malignancies
- ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer
- Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma
- Paclitaxel, Ramucirumab and Tislelizumab Switch Maintenance in Advanced HER2-negative and PD-L1 TAP Score of 5 or More Advanced Gastroesophageal Adenocarcinoma
- Panitumumab, Paclitaxel, Carboplatin and 5FU in the Treatment of Potentially Resectable Gastroesophageal Adenocarcinoma
- Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease
- Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma
- Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma